So does Victor, speaks directly to the issue that is
Item 1A: Risk Factors
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the SEC on May 12, 2014.
We believe that our cell therapy processes and procedures are exempt under PHS Section 361, CFR 1271.10 or CFR 1271.15(b) same day surgical procedure. Therefore, we do not believe that we will be required to obtain Food and Drug Administration (“FDA”) drug or biologic like approvals, although there can be no assurance that the FDA will require our products to obtain approval in the future.
must be like the piped hype dreams of company silence is now a virtue & means great things for investors & increasing the A/S another 6.5M more is great news for investors & now there is the mystery FDA approval letter but NO 8k, not found in any filing, not found in any public PR's & is now apparently only known to a few in the know via PM's although NOT known publicly NOR CAN ANY RELATED OFFICIAL INFO BE FOUND PUBLICLYDAMN FUNNY
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.